Anti-infective agents

A compound of Formula (I)

• or a pharmaceutically acceptable salt form, stereoisomer, tautomer, prodrug, salt of a prodrug, or combination thereof, wherein:
• A is a monocyclic or bicyclic ring selected from the group consisting of aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocycle;
• R1is —ORA, —O-alkyl-C(O)Y, —NRARB, —N(RC)(—N(RC)(RA)), —N(RB)L1C(O)Y or —N(RB)S(O)2Z;
• X at each occurrence, is independently selected from the group consisting of RA, —ORA and —NRARB;
• L1 is a bond or lower alkyl;
• Y at each occurrence is independently selected from the group consisting of RA, —ORA, —NRARB, —O-alkyl-ORA, —O-alkyl-NRARB, —N(RC)-alkyl-NRARB, —(CR3R4)—N(RC)C(O)X and —(CR3R4)—NRARB;
• and 2-oxo-4-(R)-phenyl-oxazolidine;
• Z at each occurrence is independently selected from the group consisting of RA, —ORA, —NRARB, -alkyl-ORA, -alkyl-NRARB, -alkyl-N(RC)C(O)X, -alkyl-O-alkyl-ORA, -alkyl-O-alkyl-NRARB and -alkyl-N(RC)-alkyl-NRARB;
• R3 and R4, at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl and arylalkyl wherein the aryl moiety of the arylalkyl is substituted with 0, 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, formyl, halo, nitro, cyano, alkoxy, —OH, —OC(O)(alkyl), —SH, —S(alkyl), —S(O)alkyl, —S(O)2(alkyl), —NH2, —N(H)(alkyl), —N(alkyl)2, —C(O)alkyl, —C(O)OH, —C(O)(—Oalkyl), —C(O)NH2, —C(O)N(H)(alkyl), —C(O)N(alkyl)2 and haloalkyl;
• RA at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, haloalkenyl, Ra and -alkylRa;
• RB at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, Ra, -alkylRa, —OH, alkoxy, hydroxyalkyl, alkoxyalkyl, —ORa, and —O-alkylRa;
• RC at each occurrence, is independently selected from the group consisting of hydrogen and lower alkyl;
• Ra at each occurrence, is independently selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle, aryl and heteroaryl;
• wherein each Ra at each occurrence is independently substituted with 0, 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, formyl, halo, nitro, cyano, alkoxy, —OH, —O-alkyl-Rb, —OC(O)(alkyl), —SH, —S(alkyl), —S(O)alkyl, —S(O)2(alkyl), —NH2, —N(H)(alkyl), —N(alkyl)2, —C(O)alkyl, —C(O)OH, —C(O)(—Oalkyl), —C(O)NH2, —C(O)N(H)(alkyl), —C(O)N(alkyl)2, haloalkyl, Rb and -alkyl-Rb;
• Rb at each occurrence is independently selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle, aryl and heteroaryl;
• wherein each Rb at each occurrence is independently substituted with 0, 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, formyl, halo, nitro, cyano, alkoxy, —OH, —OC(O)(alkyl), —SH, —S(alkyl), —S(O)alkyl, —S(O)2(alkyl), —NH2, —N(H)(alkyl), —N(alkyl)2, —C(O)alkyl, —C(O)OH, —C(O)(—Oalkyl), —C(O)NH2, —C(O)N(H)(alkyl), —C(O)N(alkyl)2 and haloalkyl;
• R2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, Ra, -alkyl-Ra, -alkenyl-Ra, -alkynyl-Ra, haloalkyl, hydroxyalkyl, formylalkyl, cyanoalkyl, -alkyl-ORA, and -alkyl-NRARB;
• R5, R6, R7 and R8 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cyano, formyl, halo, nitro, —ORA, —OC(O)RA, —OC(O)ORA, —OC(O)NRARB, —OS(O)2RA, —SRA, —S(O)RA, —S(O)2RA, —S(O)2(ORA), —S(O)2NRARB, —NRARB, —N(RC)C(O)RA, —N(RC)C(O)NRARB, —N(RC)C(O)ORA, —N(RC)S(O)2RA, —N(RC)S(O)2NRARB, —N(RC)S(O)2N(RC)C(O)ORA, —C(O)RA, —C(O)ORA, —C(O)NRARB, haloalkyl, cyanoalkyl, -alkylORA, -alkyl-OC(O)RA, -alkyl-OC(O)ORA, -alkyl-OC(O)NRARB, -alkyl-OS(O)2RA, -alkyl-SRA, -alkyl-S(O)RA, -alkyl-S(O)2RA, -alkyl-S(O)2(ORA), -alkyl-S(O)2NRARB, -alkyl-NRARB, -alkyl-N(RC)C(O)RA, -alkyl-N(RC)C(O)NRARB, -alkyl-N(RC)C(O)ORA, -alkyl-N(RC)S(O)2RA, -alkyl-N(RC)S(O)2NRARB, -alkyl-N(RC)S(O)2N(RC)C(O)ORA, -alkyl-C(O)RA, -alkyl-C(O)(ORA) and -alkyl-C(O)NRARB;
• R9 is —ORA, —SRA, —NRARB, —N(RC)C(O)RA, —N(RC)C(O)ORA, —N(RC)S(O)2RA or —N(RC)S(O)2NRARB;
• n is 0, 1, 2, 3 or 4;
• R10 at each occurrence is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cyano, formyl, nitro, halo, Ra, —ORA, —OC(O)X, —OS(O)2RA, —O-alkyl-G1, —SRA, —S(O)RA, —S(O)2X, —NRARB, —N(RB)C(O)X, —N(RB)C(O)(-alkyl-G1), —N(RB)S(O)2X, —N(RB)S(O)2(-alkyl-G1), —C(O)X, —C(O)N(RB)(-alkyl-G1), haloalkyl, cyanoalkyl, nitroalkyl, -alkyl-Ra, —N(-alkyl-C(O)X)(S(O)2X) and -alkyl-G1;
• G1 is selected from the group consisting of —ORA, —NRARB, —N(RC)(—NRARB), —N(RC)S(O)2X, —N(RC)C(O)X, —C(O)X, —OC(O)X and —S(O)2X;
• and
• R11 is selected from the group consisting of hydrogen, alkyl, alkenyl and arylalkyl;
• wherein the aryl moiety of the arylalkyl is substituted with 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, formyl, halo, nitro, cyano, haloalkyl, —OH, alkoxy, —OC(O)(alkyl), —NH2, —N(H)(alkyl), —N(alkyl)2, —C(O)OH, —C(O)(—Oalkyl), —C(O)alkyl, —C(O)NH2, —C(O)N(H)(alkyl) and —C(O)N(alkyl)2.